Company research
Cytek Biosciences, Inc.
CIK 1831915Updated Sep 27, 2026
SecurityCTKB · NASDAQ · equity
CTKB price & chart
Loading TradingView…
NASDAQ:CTKB on TradingView ↗About the company
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS, Cytek Aurora™ Evo, and Cytek Borealis™ systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.
In the news
Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding ↗
Recent filings
144 filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
4 filing
4 filing
10-Q filing
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Submission of Matters to a Vote of Security Holders
Items 5.07
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 461,542,000Source | 499,500,000Source | 494,457,000Source | 519,476,000Source |
| Property, Plant and Equipment, NetUSD | 18,009,000Source | 17,962,000Source | 18,405,000Source | 13,682,000Source |
| GoodwillUSD | 16,697,000Source | 16,663,000Source | 16,183,000Source | 10,144,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 16,821,000Source | 20,128,000Source | 23,084,000Source | 4,331,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 90,853,000Source | 98,716,000Source | 167,299,000Source | 296,601,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 62,509,000Source | 60,588,000Source | 55,928,000Source | 48,864,000Source |
| Inventory, NetUSD | 48,428,000Source | 43,893,000Source | 60,877,000Source | 48,154,000Source |
| Assets, CurrentUSD | 391,996,000Source | 396,446,000Source | 392,060,000Source | 454,020,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 19,530,000Source | 14,075,000Source | 12,514,000Source | 12,954,000Source |
| Operating Lease, Right-of-Use AssetUSD | 11,315,000Source | 10,168,000Source | 10,853,000Source | 13,883,000Source |
| Other Assets, NoncurrentUSD | 6,704,000Source | 4,759,000Source | 3,385,000Source | 2,957,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 119,803,000Source | 103,763,000Source | 101,393,000Source | 93,930,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 129,000Source | 129,000Source | 131,000Source | 135,000Source |
| Additional Paid in CapitalUSD | 441,107,000Source | 430,791,000Source | 423,386,000Source | 442,887,000Source |
| Retained Earnings (Accumulated Deficit)USD | -101,738,000Source | -35,199,000Source | -29,178,000Source | -17,030,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 2,241,000Source | 16,000Source | -1,275,000Source | -697,000Source |
| Stockholders' Equity Attributable to ParentUSD | 341,739,000Source | 395,737,000Source | 393,064,000Source | 425,546,000Source |
| Liabilities and EquityUSD | 461,542,000Source | 499,500,000Source | 494,457,000Source | 519,476,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 77,804,000Source | 67,663,000Source | 56,226,000Source | 49,040,000Source |
| Operating Lease, Liability, CurrentUSD | 2,880,000Source | 3,756,000Source | 2,444,000Source | 2,931,000Source |
| Operating Lease, Liability, NoncurrentUSD | 14,042,000Source | 7,552,000Source | 9,479,000Source | 12,312,000Source |
| Other Liabilities, NoncurrentUSD | 2,307,000Source | 2,364,000Source | 2,431,000Source | 1,587,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 23,417,000Source | 21,443,000Source | 20,035,000Source | 21,126,000Source |
| Deferred Revenue, CurrentUSD | 28,504,000Source | 25,492,000Source | 22,695,000Source | 12,986,000Source |
| Deferred Revenue, NoncurrentUSD | 18,339,000Source | 16,098,000Source | 15,132,000Source | 13,124,000Source |
| Deferred Tax Liabilities, NetUSD | 182,000Source | 2,580,000Source | 3,212,000Source | 4,048,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -66,539,000Source | -6,020,000Source | -12,148,000Source | 2,484,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 7,579,000Source | 7,212,000Source | 6,048,000Source | 2,492,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 24,585,000Source | 26,848,000Source | 22,048,000Source | 16,595,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -368,000Source | 5,428,000Source | 7,332,000Source | 19,744,000Source |
| Increase (Decrease) in InventoriesUSD | 5,244,000Source | -14,755,000Source | -4,286,000Source | 17,653,000Source |
| Increase (Decrease) in Accounts PayableUSD | 448,000Source | 2,582,000Source | -1,784,000Source | 1,862,000Source |
| Deferred Income Tax Expense (Benefit)USD | 33,557,000Source | -2,886,000Source | -10,029,000Source | -11,285,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -4,686,000Source | 25,379,000Source | 5,281,000Source | -12,231,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 10,117,000Source | -82,974,000Source | -93,894,000Source | -55,909,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 4,084,000Source | 3,525,000Source | 4,648,000Source | 9,748,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | 15,074,000Source | 21,611,000Source | 44,151,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -13,432,000Source | -15,822,000Source | -41,812,000Source | 5,513,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -7,892,000Source | -68,885,000Source | -131,870,000Source | -65,118,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 90,853,000Source | 98,745,000Source | 167,630,000Source | 299,500,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 2,159,000Source | 3,828,000Source | 5,305,000Source | 10,390,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 109,000Source | 4,532,000Source | -1,445,000Source | -2,491,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 24,585,000Source | 26,848,000Source | 22,048,000Source | 16,595,000Source |
| Amortization of Intangible AssetsUSD | 3,700,000Source | 3,700,000Source | 3,300,000Source | 835,000Source |
| DepreciationUSD | 3,900,000Source | 3,500,000Source | 2,800,000Source | 1,700,000Source |
| Equity Securities, FV-NI, Gain (Loss)USD | — | — | 0Source | 0Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -415,000Source | -55,000Source | -7,000Source | — |
| Gain (Loss) Related to Litigation SettlementUSD | -1,000,000Source | — | — | — |
| General and Administrative ExpenseUSD | 58,936,000Source | 43,113,000Source | 43,972,000Source | 34,690,000Source |
| GoodwillUSD | 16,697,000Source | 16,663,000Source | 16,183,000Source | 10,144,000Source |
| Income Tax Expense (Benefit)USD | 36,698,000Source | 320,000Source | -3,561,000Source | -1,224,000Source |
| InterestExpenseNonoperatingUSD | 474,000Source | -5,239,000Source | — | — |
| Inventory Write-downUSD | 1,703,000Source | 1,646,000Source | 1,468,000Source | 756,000Source |
| Investment Income, InterestUSD | 2,216,000Source | 5,121,000Source | 6,413,000Source | 4,619,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | 58,000Source | 97,000Source | -29,000Source | 17,000Source |
| Net Income (Loss) Attributable to ParentUSD | -66,539,000Source | -6,020,000Source | -12,148,000Source | 2,484,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 0Source | 0Source | 0Source | 92,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -66,539,000Source | -6,020,000Source | -12,148,000Source | 2,576,000Source |
| Nonoperating Income (Expense)USD | 10,543,000Source | 14,823,000Source | 12,136,000Source | 3,064,000Source |
| Operating ExpensesUSD | 144,844,000Source | 131,629,000Source | 137,271,000Source | 102,778,000Source |
| Other Nonoperating Income (Expense)USD | 8,801,000Source | 4,463,000Source | 7,794,000Source | 1,018,000Source |
| Proceeds from Stock Options ExercisedUSD | 325,000Source | 1,015,000Source | 1,468,000Source | 1,204,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 201,493,000Source | 200,453,000Source | 193,015,000Source | 164,036,000Source |
| Cost of RevenueUSD | 97,033,000Source | 89,347,000Source | 83,589,000Source | 63,062,000Source |
| Operating Income (Loss)USD | -40,384,000Source | -20,523,000Source | -27,845,000Source | -1,804,000Source |
| Other Nonoperating Income (Expense)USD | 8,801,000Source | 4,463,000Source | 7,794,000Source | 1,018,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -29,841,000Source | -5,700,000Source | -15,709,000Source | 1,260,000Source |
| Income Tax Expense (Benefit)USD | 36,698,000Source | 320,000Source | -3,561,000Source | -1,224,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 0Source | 0Source | 0Source | 92,000Source |
| Net Income (Loss) Attributable to ParentUSD | -66,539,000Source | -6,020,000Source | -12,148,000Source | 2,484,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.09Source | 0.02Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.09Source | 0.02Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 127,745,939Source | 130,611,330Source | 135,283,044Source | 134,510,831Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 127,745,939Source | 130,611,330Source | 135,283,044Source | 138,562,111Source |
| Interest Expense (non-operating)USD | 474,000Source | -5,239,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 3,700,000Source | 3,700,000Source | 3,300,000Source | 835,000Source |
| Business Combination, Acquisition Related CostsUSD | — | — | 1,500,000Source | — |
| Current Income Tax Expense (Benefit)USD | 3,141,000Source | 3,206,000Source | 6,468,000Source | 10,061,000Source |
| Gain (Loss) Related to Litigation SettlementUSD | -1,000,000Source | — | — | — |
| General and Administrative ExpenseUSD | 58,936,000Source | 43,113,000Source | 43,972,000Source | 34,690,000Source |
| Gross ProfitUSD | 104,460,000Source | 111,106,000Source | 109,426,000Source | 100,974,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -44,492,000Source | -12,778,000Source | -16,899,000Source | -1,347,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | -0.52Source | -0.05Source | -0.09Source | 0.02Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | -0.52Source | -0.05Source | -0.09Source | 0.02Source |
| Interest ExpenseUSD | — | — | 2,071,000Source | 2,573,000Source |
| Investment Income, InterestUSD | 2,216,000Source | 5,121,000Source | 6,413,000Source | 4,619,000Source |
| Marketing and Advertising ExpenseUSD | 4,200,000Source | 3,800,000Source | 3,400,000Source | 2,500,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -66,539,000Source | -6,020,000Source | -12,148,000Source | 2,576,000Source |
| Nonoperating Income (Expense)USD | 10,543,000Source | 14,823,000Source | 12,136,000Source | 3,064,000Source |
| Operating ExpensesUSD | 144,844,000Source | 131,629,000Source | 137,271,000Source | 102,778,000Source |
| Research and Development ExpenseUSD | 36,468,000Source | 39,402,000Source | 44,151,000Source | 34,858,000Source |
| Selling and Marketing ExpenseUSD | 49,440,000Source | 49,114,000Source | 49,148,000Source | 33,230,000Source |
| Undistributed Earnings (Loss) Allocated to Participating Securities, BasicUSD | — | — | 0Source | 0Source |
Filing attachments
d137695dex991.htm · 8-K · 2026-08-24
EX-99.1 2 d137695dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding FREMONT, Calif., August 21, 2026 (GLOBE NEWSWIRE) - Cytek Biosciences, Inc. (“Cytek Biosciences,” “Cytek,” or the “Company”) (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that a jury in the United States District Court for the District of Delaware returned a verdict in the patent infringement action brou…
Read attachment ↗d118986dex991.htm · 8-K · 2026-08-05
EX-99.1 2 d118986dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Cytek Biosciences Reports Second Quarter 2026 Financial Results FREMONT, Calif., August 5, 2026 (GLOBE NEWSWIRE) - Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2026. Recent Highlights Total revenue for the second quarter of 2026 was $48.1 million, representing a 6% increase compared to the…
Read attachment ↗d146722dex991.htm · 8-K · 2026-05-07
EX-99.1 2 d146722dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Cytek Biosciences Reports First Quarter 2026 Financial Results FREMONT, Calif., May 7, 2026 (GLOBE NEWSWIRE) - Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2026. Recent Highlights Total revenue for the first quarter of 2026 was $44.1 million, representing a 6% increase compared to the fi…
Read attachment ↗